Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Cresemba

CRESEMBA 200 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 9–10

HOS-128908 · Präparat HOS-096645

(Mechanism unknown) Other anticancer agents Not studied. No isavuconazole dose (daunorubicin, doxorubicin, Daunorubicin, doxorubicin, adjustment necessary. imatinib, irinotecan, lapatinib, imatinib, irinotecan, lapatinib, Daunorubicin, doxorubicin, mitoxantrone, topotecan) mitoxantrone, topotecan imatinib, irinotecan, lapatinib, (BCRP substrates) concentrations may increase. mitoxantrone or topotecan: careful monitoring for any (BCRP inhibition) occurrence of drug toxicity, and dose reduction if required. Antiemetics Aprepitant Not studied. Co-administration should be (mild CYP3A4/5 inducer) Isavuconazole concentrations may avoided unless the potential decrease. benefit is considered to outweigh the risk. (CYP3A4/5 induction) Antidiabetics Metformin Metformin: No isavuconazole dose (OCT1, OCT2 and MATE1 AUCinf: ↑ 52% adjustment necessary. substrate) Cmax: ↑ 23% Metformin: dose reduction may be required. (OCT2 inhibition) Repaglinide Repaglinide: No isavuconazole dose (CYP2C8 and OATP1B1 AUCinf: ↓ 8% adjustment necessary. substrate) Cmax: ↓ 14% Repaglinide: no dose adjustment required. Pioglitazone Not studied. Co-administration should be (mild CYP3A4/5 inducer) avoided unless the potential 9  Isavuconazole concentrations may benefit is considered to outweigh decrease. the risk.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daunorubicin (HOS-089674) aprepitant (HOS-112506) imatinib (HOS-110212) lapatinib (HOS-122565) pioglitazone (HOS-089663) mitoxantrone (HOS-124775) topotecan (HOS-086047) doxorubicin (HOS-084538) irinotecan (HOS-112102) repaglinide (HOS-086935) metformin (HOS-091032)